Talk: Hypomethylating Agent in Patients with MDS
0 likes346 views
The document announces a dinner lecture on using hypomethylating agents to treat myelodysplastic syndromes. The event will feature an international speaker, Dr. Antonio Pinto from Italy, who will discuss treatment schedules and preventing side effects. It provides details on the date, time, venue, speaker biography and contact information to RSVP for the buffet dinner.
Talk: Hypomethylating Agent in Patients with MDS
- 2. Cordially invites you to attend a Dinner Lecture “How to use Hypomethylating Agent in Patients with MDS: Focus on Treatment Schedule and Prevention of Side Effect” International Speaker Chairperson Dr Antonio Pinto Dato’ Dr Chang Kian Meng Head, Hematology/Oncology Unit Head, Department of Haematology National Cancer Institute Hospital Ampang Fondazione ‘Pascale’ President Head, Department of Hematology Malaysian Society of Haematology Istituto Pascale IRCCS, Naples, Italy Date: March 8, 2011 (Tuesday) Time: 1900- 2200 hrs Venue: Hilton Kuala Lumpur Suite 2 & 3, Level 7 Dr. Antonio Pinto graduated in Medicine in 1981 and obtained the Specialty Board Certification in Oncology and in Clinical Hematology. He gained clinical and research experience during different training periods in Oncology/Hematology in the UK (University of London, St. Thomas’ Hospital, Northwick Park Hospital; University of Glasgow) and Australia (University of Melbourne, Ludwig Institute for Cancer Research). Dr. Pinto joined in 1987 the Centro di Riferimento Oncologico, Aviano, Italy where he served as Head of the Developmental Oncology/Hematology and Leukemia Unit up to November 2000. From December 2000 to date, he is serving as Head of the Hematology/Oncology Unit of the National Cancer Institute, Fondazione ‘Pascale’, IRCCS, Naples, Italy. Starting from march 2008 he was appointed as Head of the new Department of Hematology at the Istituto Pascale, IRCCS, Naples, Italy. Dr. Pinto has published several studies addressing the relevance of cell contact-dependent and cytokine-mediated interactions between Reed-Sternberg cells and reactive cell populations in tissues involved by Hodgkin’s disease. He has also unveiled the role of some TNF-superfamily receptors and ligands and of CD138 (Syndecan-1) in human leukemias and Hodgkin’s lymphoma. He concurrently coordinated the clinical development in Europe of DNA-methyltransferases inhibitor 5-aza-2’-deoxycytidine (Decitabine) by designing and conducting phase I and II trials in leukemia and myelodysplastic syndromes, becaming member of the international working group (IWG) for response criteria in myelodysplasia. Dr. Pinto currently coordinates phase II trials on newer upfront and salvage regimes for Hodgkin’s and non-Hodgkin lymphoma and GCP phase III studies with upfront experimental regimes in lymphomas and multiple myeloma. He acted as member of the National Comittee for Evaluation of Supported by an Phase I Clinical Trials (Commissione Ministeriale per l'accertamento dei requisiti dei prodotti farmaceutici di educational nuova istituzione, ex art.7 D.P.R. 439/2001) and of the Working Party for non conventional cancer treatments, grant from Consiglio Superiore di Sanità, National Ministry of Health, Rome, Italy. Dr. Pinto authored more than 160 papers on high-rank international journals, with a personal IF > 650. Buffet Dinner will be provided. Limited seats available. • RSVP • by March 01, 2011 • Wong Chee Keong: +65 9177 4866 / ckwong@celgene.com • • Juls: +65 6572 5131 / jbjalil@celgene.com •
- 3. SPEAKER AND TITLE TIME Registration 19:00-19:30 DR ANTONIO PINTO How to use Hypomethylating Agent in Patients with MDS: 19:30-20:10 Focus Treatment Schedule and Prevention of Side Effect Q&A 20:10-20:30 20:30 DINNER onwards